Christy Su

ID/ASP PharmD | @tbhcpharmres ➡️ @memorialhermann ➡️ @MethodistHosp | #antimicrobialstewardship

[Gonzalo Bearman @gonzalobearman]

#IDTwitter @ASHE_Journal Implementation of a hospital-wide EHR-integrated antibiotic challenge order set https://t.co/MNySmzoB8g

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

Antibiotics were more commonly prescribed to toxin-positive patients (98%) than toxin-negative patients (56%) (p < 0.01). Of the 90 patients who were toxin-negative, 44% of those were not treated with antibiotics* #IDXposts
*Even if they have diarrhea?!

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

The only one left is Candida albicans

[Lisa Dumkow @LisaIDpharmD]

‼️Just shared at #IDWeek2025, our findings are now published in @OFIDJournal comparing cephalexin to cefdinir for uUTI in females. Spoiler: cefdinir was the only independent risk factor associated with/failure. Poor urinary PK = ⬆️failure. Let’s stop Rx’ing cefdinir for UTI! 🛑💊

[Brent C. Beckner PharmD, BCPS, BCCCP @BCB_PharmD]

Would have liked to see keflex 1g Q8 but useful chart none the less

[Takahiro Matsuo (Taka), MD @TakaMatsuo_ID]

【Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults】@TheLancetInfDis Aug 2025

👉Uncomplicated candidaemia redefined
👉Controlled source, clinical response, and bloodstream clearance ≤ 5 days = uncomplicated
👉Shorter antifungal courses may be safe, RCTs needed

https://t.co/itlAJa35Iy

#IDMedEd #IDFellow @MSG_ERC @eurconfmedmycol

[Timothy Li @drtimothyli]

Rationale behind the use of high-dose sulbactam (SUL) against CRAB infections

Conventional dose:
SUL hydrolysed by β-lactamases➡️cannot reach their targets (PBP1a/1b/3)

High-dose, extended-infusion therapy can overcome the hydrolysis by β-lactamases

https://t.co/q3rDfsziLU

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🔥Just published 🔥
Blood Culture–Negative Endocarditis: A Scientific Statement From the American Heart Association: Endorsed by the International Society for Cardiovascular
Infectious Diseases
Thanks @Inox94 @myfizi
Read the note about gentamicin fig-3
https://t.co/WZbb731zXt

[IDSA @IDSAInfo]

An updated guideline on the treatment of #TB in children and adults is now available! ⬇️ https://t.co/hiM7GUPK8Y

Developed by IDSA, @atscommunity, @CDCgov and @EuroRespSoc, the guideline is for settings where diagnostic tools like mycobacterial cultures are routinely available.

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🔥Just published🔥 @TheLancetInfDis @CornelyOliver
@RosanneSprute
Global guideline for the diagnosis and management of candidiasis: an an initiative of the @eurconfmedmycol in cooperation with @ISHAM_Mycology & @ASMicrobiology
https://t.co/pEG8M0uaQP

[JAMA Network Open @JAMANetworkOpen]

This consensus statement creates a clinical guideline for the diagnosis and management of UTIs that addresses the gap between the evidence and recommendation strength. https://t.co/c1nnbwewIz @bradspellberg

[Timothy Li @drtimothyli]

Proposed assessment framework for patients with suspected UTI who live in long-term care facilities from @Wiki_Guidelines

⭐No more urinalysis or urine culture simply for altered mental state/smelly urine/cloudy urine
⭐If other causes of fever are present, skip the urine tests

[Paul Sax @PaulSaxMD]

I know you’ve all been on tenterhooks, awaiting the dramatic conclusion to “How PCP Became PJP”.
Well here it is.
You’ll laugh! You’ll cry! And you’ll finish reading it so much better informed about this critical debate. @JWatch @NEJM https://t.co/wDolWBB4NW

[Lisa Dumkow @LisaIDpharmD]

Great presentation by @bryan_p_white on optimal durations of therapy for empyema which is currently an “evidence light” area of practice. 2-6 weeks currently recommended based on limited data - shorter probably better for some? Loved the personal letter to end! #IDWeek2024

[Lisa Dumkow @LisaIDpharmD]

@IDPharmD_Kate crushing it & getting everyone talking about, is this really AKI when it comes to vanco + pip/tazo? And coining the term fake-KI 🤩 Her key lesson…we probably don’t need vanco (or pip/tazo) for most patients! #IDWeek2024 #SIDP2024

[Michael Calderwood, MD, MPH @CalderwoodMD]

More is not always better. Adding vancomycin to cefazolin as surgical prophylaxis in patients undergoing arthroplasty does not improve outcomes in patients not known to be MRSA colonized. Outcomes WORSE for knee arthroplasty. Just don't. https://t.co/r9ZzYpZJXS #IDWeek2024

[Michael Calderwood, MD, MPH @CalderwoodMD]

I love these two slides on the evidence for combination therapy in persistent MRSA and MSSA bacteremia. References in footer of each slide. #IDWeek2024

[Bug Pharmacist 💊🧫 Tim Gauthier @IDstewardship]

📄 Over a year in the making, I’m excited to share my latest pub, which I hope is helpful for people learning about infectious diseases.

🙌 Huge shout out to amazing co-authors Dr. Landayan, Dr. Cady, and Dr. Liu

💎There are a ton of great resources out there, many of those are available here

🗣️The discussion on teaching strategies is meant to help teachers realize and pick through all the wonderful options at their fingertips

📲 https://t.co/b158Lv4o1G

[Takahiro Matsuo (Taka), MD @TakaMatsuo_ID]

【A narrative review on antimicrobial dosing in adult critically ill patients on ECMO】Critical Care, Oct 2, 2024

👉Congrats to our 2nd-year fellow, MJ, @IDdocAdi, and team @MayoClinicINFD!

👉Comprehensive review of ECMO literature on pharmacokinetics and pharmacodynamics of antimicrobials!

https://t.co/q9wZYe3Xlx

#IDMedEd #IDFellow